Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Eli Lilly and Company : The underlying trend is in force again

10/16/2020 | 09:10am EDT
long trade
Stop-loss triggered
Entry price : 147.11$ | Target : 169.13$ | Stop-loss : 139$ | Potential : 14.97%
Shares in Eli Lilly and Company do not show any sign of a slowdown in the ascending dynamic. Investors could bet on a continuation of the underlying trend.
Investors have an opportunity to buy the stock and target the $ 169.13.
Eli Lilly and Company : Eli Lilly and Company : The underlying trend is in force again
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.

  • The share is getting closer to its long-term support in weekly data, at USD 141.46, which offers good timing for buyers.
  • Graphically speaking, the timing seems perfect for purchasing the stock close to the USD 141.52 support.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.
  • The stock is in a well-established, long-term rising trend above the technical support level at 141.46 USD

  • Based on current prices, the company has particularly high valuation levels.

ę MarketScreener.com 2020

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (USD)
Sales 2021 27 273 M - -
Net income 2021 6 537 M - -
Net Debt 2021 11 042 M - -
P/E ratio 2021 31,1x
Yield 2021 1,47%
Capitalization 206 B 206 B -
EV / Sales 2021 7,94x
EV / Sales 2022 7,72x
Nbr of Employees 35 000
Free-Float 99,8%
Upcoming event on ELI LILLY AND COMPANY
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 221,09 $
Last Close Price 226,10 $
Spread / Highest target 19,4%
Spread / Average Target -2,22%
Spread / Lowest Target -22,6%
EPS Revisions
Managers and Directors
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Diogo Rau Senior VP, Chief Information & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON5.08%434 405
ROCHE HOLDING AG10.68%328 612
PFIZER, INC.7.66%224 747
NOVARTIS AG-0.39%208 035
ABBVIE INC.7.70%203 857